首页> 外文期刊>Clinical and experimental ophthalmology >Collagen cross-linking: a new treatment paradigm in corneal disease - a review.
【24h】

Collagen cross-linking: a new treatment paradigm in corneal disease - a review.

机译:胶原蛋白交联:角膜疾病的一种新治疗方法-综述。

获取原文
获取原文并翻译 | 示例
           

摘要

The last 2 years has seen a marked increase in the prominence of corneal collagen cross-linking as a treatment strategy for progressive keratoconus. This interest has arisen from a body of laboratory evidence documenting the biomechanical and cellular changes induced by cross-linking. The findings of this research provide a plausible rationale for its use in keratoconus to retard the progression of this common disease. The rapidly growing number of clinical reports suggests, not only a consistent stabilizing effect of cross-linking, but that a variable improvement in corneal shape and visual function may also occur in some patients. However, the marked variation in the clinical course of keratoconus, together with the challenges of accurately evaluating refractive error, visual acuity and even corneal shape in this condition, demands further evidence from randomized controlled clinical trials. The aim of this review is to summarize the theoretical basis and risks of corneal collagen cross-linking, along with the available evidence for its use in keratoconus and other corneal disease states.
机译:在过去的两年中,作为进行性圆锥角膜的治疗策略,角膜胶原蛋白交联的突出性显着增加。这种兴趣来自大量的实验室证据,这些证据记录了由交联引起的生物力学和细胞变化。这项研究的发现为其在圆锥角膜中延缓这种常见疾病的进展提供了合理的理由。快速增长的临床报告表明,不仅交联具有稳定的稳定作用,而且某些患者还可能发生角膜形状和视觉功能的不同改善。然而,圆锥角膜临床过程的显着变化,以及在这种情况下准确评估屈光不正,视敏度甚至角膜形状的挑战,都需要来自随机对照临床试验的进一步证据。这篇综述的目的是总结角膜胶原蛋白交联的理论基础和风险,以及在角膜圆锥角膜和其他角膜疾病中使用的现有证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号